Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Ysios Capital is a prominent European venture capital firm founded in 2008, with offices strategically located in San Sebastián and Barcelona, Spain. The firm specializes in investing in biotech companies that are dedicated to developing innovative therapeutic drugs aimed at addressing significant unmet medical needs. With over €400 million in assets under management, Ysios Capital has established itself as a key player in the biotech sector, particularly within Spain, where it has significantly contributed to the growth and development of the industry. The firm’s leadership comprises experienced professionals with deep expertise in the biotech field, enabling them to identify and nurture promising ventures. Ysios Capital’s reputation is built on its commitment to transforming capital into medical breakthroughs, making it a sought-after partner for startups in the biotech space.
Ysios Capital's investment focus is primarily on biotech ventures that are engaged in the development of innovative therapeutic drugs across various modalities and therapeutic areas. The firm actively supports companies at different stages of development, with a particular emphasis on late preclinical and early clinical projects. Their investment strategy encompasses both asset-centric companies and product-enabling platform technologies, ensuring a diverse portfolio that reflects the dynamic nature of the biotech landscape. Ysios Capital seeks to partner with companies that possess strong scientific foundations and demonstrate the potential for clinical efficacy. By concentrating on these critical areas, the firm aims to foster advancements in healthcare that can lead to significant improvements in patient outcomes globally.
Ysios Capital boasts a diverse portfolio of 12 innovative biotech companies, each contributing to the advancement of healthcare through groundbreaking therapies. Notable investments include **Adcendo** from Denmark, which is developing targeted anti-cancer therapies based on antibody-drug conjugates, and **Anaconda Biomed** from Spain, focused on innovative solutions for ischemic stroke. In the United States, **Aura Biosciences** utilizes nanotechnology for cancer treatment, while **Neurona Therapeutics** is pioneering regenerative cell therapies for nervous system repair. Other significant portfolio companies include **Cytoki Pharma** (Denmark), which develops protein drugs for diseases like Inflammatory Bowel Disease, and **LAVA Therapeutics** (Netherlands), creating bispecific antibodies for treating various cancers. This diverse array of companies highlights Ysios Capital's commitment to supporting transformative healthcare solutions.
To pitch Ysios Capital, founders should prepare a detailed presentation that highlights their innovative approach and scientific foundation. While specific submission guidelines are not provided, a compelling narrative that addresses unmet medical needs is crucial. Warm introductions are likely preferred, given the firm's focus on building strong relationships.
Ysios Capital invests across multiple stages, including pre-seed, seed, Series A, Series B, and Series C. This broad investment range allows them to support companies at various points in their development journey, particularly those in late preclinical and early clinical phases.
Founders interested in pitching to Ysios Capital should prepare a comprehensive presentation that outlines their business model, scientific foundation, and potential for clinical efficacy. While specific pitch submission details are not provided, a well-structured approach highlighting innovation and market need is essential.
Ysios Capital primarily focuses on the biotech sector, specifically investing in companies that develop innovative therapeutic drugs. Their investment strategy emphasizes addressing high unmet medical needs across various therapeutic areas.
While specific check sizes are not disclosed, Ysios Capital's investment strategy spans multiple stages, suggesting flexibility in funding amounts based on the needs and potential of the companies they support.
Ysios Capital invests globally, with a strong emphasis on Europe. Their portfolio includes companies from various countries, reflecting their commitment to supporting innovative biotech solutions worldwide.
Ysios Capital engages actively with its portfolio companies, providing not only financial support but also strategic guidance and industry connections to help accelerate their growth and development in the competitive biotech landscape.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.